Shopping Cart
Remove All
Your shopping cart is currently empty
Xanomeline oxalate (LY246708 oxalate), a potent and selective muscarinic receptor agonist (SMRA), effectively stimulates in vivo phosphoinositide hydrolysis. It is a valuable compound for Alzheimer's disease research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $32 | In Stock | In Stock | |
| 10 mg | $53 | In Stock | In Stock | |
| 25 mg | $107 | In Stock | In Stock | |
| 50 mg | $171 | In Stock | In Stock | |
| 100 mg | $272 | In Stock | In Stock | |
| 200 mg | $392 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $35 | In Stock | In Stock |
| Description | Xanomeline oxalate (LY246708 oxalate), a potent and selective muscarinic receptor agonist (SMRA), effectively stimulates in vivo phosphoinositide hydrolysis. It is a valuable compound for Alzheimer's disease research. |
| In vitro | Xanomeline stimulates phosphoinositide (PI) hydrolysis in A9 L m1 cells and inhibits [3H]-PZ and [3H]-OXO-M binding to rat brain, with Kis of 7 and 3 nM, respectively[1]. |
| In vivo | Xanomeline robustly stimulates in vivo PI hydrolysis, an effect blocked by muscarinic antagonists, indicating mediation by muscarinic receptors. In mice, the ED100 for Xanomeline-induced stimulation of [3H]-IP accumulation in the hippocampus is 54 μmole/kg, while in rats, it is 8.1 μmole/kg in the hippocampus[1]. |
| Synonyms | LY246708 oxalate |
| Molecular Weight | 371.45 |
| Formula | C16H25N3O5S |
| Cas No. | 141064-23-5 |
| Smiles | OC(=O)C(O)=O.CCCCCCOc1nsnc1C1=CCCN(C)C1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (121.15 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.38 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.